Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026)

Fortrea Holdings (FTRE) posted Non-Current Deferred Tax Liability of $92.3 million for Q1 2026, down 5.43% on a QoQ basis from $97.6 million in Q4 2025, and down 21.71% year-over-year from $117.9 million in Q1 2025.

Fortrea Holdings (FTRE) Non-Current Deferred Tax Liability (2022 - 2026) Analysis & Trends

Fortrea Holdings' Non-Current Deferred Tax Liability history runs 5 years deep, the most recent figure standing at $92.3 million for Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability fell 21.71% year-over-year to $92.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.3 million (down 21.71% YoY) and the FY2025 annual result came in at $97.6 million, down 19.8% from the prior year.
  • Non-Current Deferred Tax Liability was $92.3 million for Q1 2026 at Fortrea Holdings, down from $97.6 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $184.5 million in Q4 2022 and bottomed at $92.3 million in Q1 2026.
  • A 5-year average of $134.7 million and a median of $126.9 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability declined 26.11% — and 2025, when it retreated 15.76%.
  • Fortrea Holdings' Non-Current Deferred Tax Liability stood at $184.5 million in 2022, then fell by 19.95% to $147.7 million in 2023, then decreased by 17.6% to $121.7 million in 2024, then decreased by 19.8% to $97.6 million in 2025, then retreated by 5.43% to $92.3 million in 2026.
  • Business Quant data shows FTRE's Non-Current Deferred Tax Liability at $92.3 million in Q1 2026, $97.6 million in Q4 2025, and $106.9 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Fortrea Holdings 1.83 Bn 1.68 Bn 123.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 92.30 Mn
Mar 31, 2026 92.30 Mn
Dec 31, 2025 97.60 Mn
Dec 31, 2025 97.60 Mn
Sep 30, 2025 106.90 Mn
Sep 30, 2025 106.90 Mn
Jun 30, 2025 112.80 Mn
Jun 30, 2025 112.80 Mn
Mar 31, 2025 117.90 Mn
Mar 31, 2025 117.90 Mn
Dec 31, 2024 121.70 Mn
Dec 31, 2024 121.70 Mn
Sep 30, 2024 126.90 Mn
Sep 30, 2024 126.90 Mn
Jun 30, 2024 136.10 Mn
Jun 30, 2024 136.10 Mn
Mar 31, 2024 150.70 Mn
Mar 31, 2024 150.70 Mn
Dec 31, 2023 147.70 Mn
Dec 31, 2023 147.70 Mn